Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: Exploring the cholinergic anti-inflammatory pathway

Current Alzheimer Research

Volumn 11, Issue 6, 2014, Pages 608-622

  Reale, Marcella ^a   Di Nicola, Marta ^a   Velluto, Lucia ^b   D'Angelo, Chiara ^a   Costantini, Erica ^a   Lahiri, Debomoy K ^c   Kamal, Mohammad A ^d   Yu, Qian sheng ^e   Greig, Nigel H ^e  

^a UNIVERSITY OF CHIETI   (Italy)

^b Villa Serena Hospital   (Italy)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholinesterase (AChE); Alzheimer's disease; Amyloid peptide (A ); Butyrylcholinesterase (BuChE); Cholinesterase inhibitors; Cytokines; IL 10; IL 1 ; IL 6; Inflammation; MCP 1; Phenserine, cymserine, bisnorcymserine, phytohaemagglutinin (PHA) THP 1 cells, peripheral blood mononuclear cells (PBMCs); TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BISNORCYMSERINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYMESERINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENETHYLCYMSERINE; PHENSERINE; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CCL2 PROTEIN, HUMAN; CHEMOKINE; IL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MESSENGER RNA;

AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME BLOOD LEVEL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MICROGLIAL CELL CULTURE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BUTYRYLCHOLINESTERASE; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES; CHOLINESTERASE INHIBITORS; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904754895     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205010666131212113218     Document Type: Article

References (113)

1. Prince M. Epidemiology of Alzheimer's. Psychiatry 3: 11-13 (2004)
2. Bennett DA, Launer LJ. Longitudinal epidemiologic clinicalpathologic studies of aging and Alzheimer's disease. Curr Alzheimer Res 9(6): 617-20 (2012).
3. Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res (1): 71-3 (2006).
4. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, et al. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3(1): 81-90 (2006).
5. Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, et al. Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease. Curr Alzheimer Res 4(5): 562-7 (2007).
6. Rahimi F, Shanmugam A, Bitan G. Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res 5(3): 319-41 (2008).
7. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 4(4): 378-85 (2007).
8. Schlachetzki JC, Hüll M. Microglial activation in Alzheimer's disease. Curr Alzheimer Res 6(6): 554-63, 2009.
9. McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res 1:29-39 (2008).
10. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1): a006346 (2012).
11. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 8(2): 164-74 (2011).
12. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73(10):768-74 (2009).
13. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. Biochem Soc Trans 39(4): 898-901 (2011).
14. Reale M, Kamal MA, Velluto L, Gambi D, Di Nicola M, Greig NH. Relationship between inflammatory mediators, A β levels and ApoE genotype in Alzheimer disease. Curr Alzheimer Res 9(4): 447-57 (2012).
15. Khan TK, Alkon DL. An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. Proc Natl Acad Sci USA 103(35): 13203-7 (2006).
16. Gasparin L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 12(1): 17-34 (1998).
17. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43(3): 333-44 (2004).
18. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106(12):1489-99 (2000).
19. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7): 907-13 (2003).
20. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15): 8850-5 (2001).
21. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 94(8): 4080-5 (1997).
22. Giri RK, Selvaraj SK, Kalra VK. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 170(10): 5281-94 (2003).
23. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, et al. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model. Mol Med 4(7): 480-9 (1998).
24. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558): 408-14 (1982).
25. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1(1): 1-31 (2002).
26. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the processing of beta-amyloid precursor protein in different cell lines. J Neurosci Res 37: 777-87 (1994).
27. Lahiri DK, Farlow MR, Nurnberger JI, Jr., Greig NH. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann NY Acad Sci 826: 416-21 (1997).
28. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol Brain Res 62: 131-40 (1998).
29. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98(13): 7605-10 (2001).
30. Alkalay A, Rabinovici GD, Zimmerman G, Agarwal N, Kaufer D, Miller BL, et al. Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res 10(1): 48-56 (2013).
31. Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 5(3): 233-43 (2008).
32. Rees TM, Berson A, Sklan EH, Younkin L, Younkin S, Brimijoin S, et al. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res 2(3): 291-300 (2005).
33. HuW, Gray NW, Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem 86(2): 470-78 (2003).
34. Grando SA, Kawashima K, Kirkpatrick CJ, Meurs H, Wessler I. The non-neuronal cholinergic system: basic science, therapeutic implications and new perspectives. Life Sci 91(21-22): 969-72 (2012).
35. Kawashima K, Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci 72: 2101-9 (2003).
36. Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 74: 675-96 (2003).
37. Fujii T, Takada-Takatori Y, Kawashima K. Regulatory mechanisms of acetylcholine synthesis and release by T cells. Life Sci 91(21-22): 981-5 (2012)
38. Zimring JC, Kapp LM, Yamada M, Wess J, Kapp JA. Regulation of CD8+ cytolytic T lymphocyte differentiation by a cholinergic pathway. J Neuroimmunol 164(1-2): 66-75 (2005).
39. Lane RM, Kivipelto M, Greig NH. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27(3):141-9 (2004).
40. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9(1):101-24 (2006).
41. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 102: 17213-8 (2005).
42. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesesterase. Curr Med Res Opin 17(3): 1-7 (2001).
43. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4(2):131-8 (2003).
44. Greig NH, Sambamurti K, Yu Q, Perry T, Holloway HW, Haberman F, et al. Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease. In (Eds: Giacobini E) Butyrylcholinesterase: Its Function and Inhibition. London, England, Martin Dunitz Ltd., pp 69-90 (2003).
45. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol 572(2-3):142-50 (2007).
46. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J. Excessive levels of hippocampal acetylcholine in acetylcholinesterase-knockout mice are moderated by butyrylcholinesterase activity. J Neurochem 100: 1421-8 (2007).
47. Greig NH, Yu QS, Brossi A, Matin E, Lahiri DK, Darvesh S. Butyrylcholinesterase, the Cinderella cholinesterase, as a drug target for Alzheimer's diseases and related dementias. In (Ed, Martinez, A) Medicinal Chemistry of Alzheimer's Disease Kerla, India, Transworld Research Network, Research Signpost, pp 79-109 (2008).
48. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4(4): 273-7 (1978).
49. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2(3): 307-18 (2005).
50. Ferrea S, Winterer G. Neuroprotective and neurotoxic effects of nicotine. Pharmacopsychiatry 42(6): 255-65 (2009).
51. Nordberg A, Hellström-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81(3): 655-8 (2002).
52. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacol 184(3-4):523-39 (2006).
53. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405(6785): 458-62 (2000).
54. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384-388 (2003).
55. Nizri E, Brenner T. Modulation of inflammatory pathways by the immune cholinergic system. Amino Acids 45(1): 73-85 (2013).
56. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151(7): 915-29 (2007).
57. Lee EO, Kang JL, Chong YH. The amyloid-beta peptide suppresses transforming growth factor-beta1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells. Biol Chem 280: 7845-53 (2005).
58. Yu Q, Holloway HW, Utsuki T, Brossi A, Greig NH. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 42(10): 1855-61 (1999).
59. Greig NH, Pei X-F, Soncrant T, Ingram D, Brossi A. Phenserine and ring-C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Chem Rev 15: 3-31 (1995).
60. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
61. American Psychiatric Association:Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC) (1994).
62. Ellmann GL, Coutney KD, Andres V, Featherstone RM. A new and rapid colometric determination of acetylcholinesterse activity. Biochem Pharmacol 7: 88-95 (1961).
63. Garcia-Ayllon M, Riba-Liena I, Serra-Basante C, Alom J, Boopathy R, Saez-Valero J. Altered levels of Acetylcholinesterase in Alzheimer Plasma. Plos ONE 5(1): e8701 (2010).
64. Yates SL, Burgess LH, Kocsis-Angle J, Antal JM, Dority MD, Embury PB, et al. Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 74(3):1017-25 (2000).
65. Combs CK, Bates P, Karlo JC, Landreth GE. Regulation of betaamyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int 39(5-6): 449-57 (2001).
66. Teixeira AL, Reis HJ, Coelho FM, Carneiro DS, Teixeira MM, Vieira LB, et al. All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. Biol Psychiatry 64(10): 891-5 (2008).
67. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2: 281-90 (2005).
68. Rocha NP, Teixeira AL, Coelho FM, Caramelli P, Guimarães HC, Barbosa IG, et al. Peripheral blood mono-nuclear cells derived from Alzheimer's disease patients show elevated baseline levels of secreted cytokines but resist stimulation with β-amyloid peptide. Mol Cell Neurosci 49(1):77-84 (2012).
69. Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70: 596-606 (2008).
70. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 223(2): 334-46 (2010).
71. Sivanesan S, Tan A, Rajadas J. Pathogenesis of Abetaoligomers in synaptic failure. Curr Alzheimer Res 10(3): 316-23 (2013).
72. Saito Y, Buciak J, Yang J, Pardridge WM. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci USA 92: 10227-31 (1995)
73. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 70: 210-15 (1998).
74. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloidbeta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8(1):16-30 (2009).
75. Manzoni C, Colombo L, Bigini P, Diana V, Cagnotto A, et al. The molecular assembly of amyloid abeta controls its neurotoxicity and binding to cellular proteins. PLoS One 6: e24909 (2011).
76. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5: 7 (2008).
77. Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, et al. Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation 9: 106 (2012).
78. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets 10(3): 391-403 (2011).
79. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nat Rev Endocrinol 8(12): 743-54 (2012).
80. Combs CK, Karlo JC, Kao SC, Landreth GE. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21(4): 1179-88 (2001).
81. Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res 221(2): 334-40 (2011).
82. Soreq H, Zakut H. In, Human Cholinesterases and Anticholinesterases. New York: Academic Press (1993).
83. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Ann Rev Pharmacol Toxicol 34: 281-320 (1994).
84. Rosas-Ballina M, Ochani M, Parrish WR, Ochani K, Harris YT, Huston JM, et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia 105: 11008-13 (2008).
85. Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334(6052): 98-101 (2011).
86. Olofsson PS, Katz DA, Rosas-Ballina M, Levine YA, Ochani M, Valdés-Ferrer SI, et al. α7 nicotinic acetylcholine receptor (α7nAChR) expression in bone marrow-derived non-T cells is required for the inflammatory reflex. Mol Med 18: 539-43 (2012).
87. Shytle RD, Mori T, Townsend K, Vendrame M, Sun M, Zeng J, et al. Cholinergic modulation of microglia activation by a 7 nicotinic receptors. J. Neurochem 89: 337-43 (2004).
88. Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol 11(3): 356-63 (2012).
89. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging 30: 337-52 (2009).
90. Reale M, Iarlori C, Feliciani C, Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 14(2):147-59 (2008).
91. Reale M, Iarlori C, Gambi F, Feliciani C, Isabella L, Gambi D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacol 50(5): 606-13 (2006).
92. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 69(6):1272-6 (2007).
93. Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci 9(3): 220-34 (1997).
94. Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons J Neurochem 74(1): 125-33 (2000).
95. Abe K, Saito H. Amyloid beta neurotoxicity not mediated by the mitogen-activated protein kinase cascade in cultured rat hippocampal and cortical neurons. Neurosci Lett 292(1): 1-4 (2000).
96. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 33:597-605 (2003).
97. Kim YH, Choi KH, Park JW, Kwon TK. LY294002 inhibits LPSinduced NO production through a inhibition of NF-kappaB activation: independent mechanism of phosphatidylinositol 3-kinase. Immunol Lett 99: 45-50 (2005).
98. Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N. PI3K-Akt pathway suppresses coagulation and inflamma-tion in endotoxemic mice. Arterioscler Thromb Vasc Biol 24: 1963-9 (2004).
99. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, et al. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 172: 449-56 (2004).
100. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, et al. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann Neurology 2: 159-63 (1997).
101. Lahiri DK, Chen D, Vivien D, Ge Y-W, Greig, NH, Rogers JT. Role of cytokines in the gene expression of amyloid ß-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimers Dis 5(2): 81-90 (2003).
102. Lesné S, Docagne F, Gabriel C, Liot G, Lahiri DK, Buée L, et al. Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 278(20): 18408-18 (2003).
103. Ajit D, Udan ML, Paranjape G, Nichols MR. Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factoralpha production in the THP-1 human monocytic cell line. Biochemistry 48(38): 9011-21 (2009).
104. Klegeris A, Walker DG, McGeer PL. Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res 747(1): 114-21 (1997).
105. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2(3): 355-65 (2005).
106. Maloney B, Lahiri DK. The Alzheimer's amyloid-β peptide (Aβ)binds a specific DNA Abeta-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif. Gene 488(1-2): 1-12 (2011).
107. Bailey JA, Maloney B, Ge Y-W, Lahiri, DK. Functional activity of the novel Alzheimer's amyloid-βpeptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 488(1-2): 13-22 (2011).
108. Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 10: 3111-9 (2004).
109. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 6: 86-96 (2009).
110. Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 25(10): 2439-46 (2009).
111. Patel AN, Jhamandas JH. Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain. Expert Rev Mol Med 14: e2 (2012).
112. Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 120(1): 22-33 (2012).
113. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing 35(4): 336-8 (2006).